Low-dose aerosol model of pneumococcal pneumonia in the mouse: Utility for evaluation of antimicrobial efficacy

International Journal of Antimicrobial Agents

Volumn 26, Issue 6, 2005, Pages 497-503

  Nuermberger, Eric ^a   Helke, Kris ^b   Bishai, William R ^a  

^a Division of Infectious Diseases   (United States)

^b Medicine and Molecular Biology and Genetics   (United States)

Author keywords

Antibiotic; Carbapenem; Ertapenem; Streptococcus pneumoniae

Indexed keywords

ERTAPENEM;

AEROSOL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL COUNT; CONTROLLED STUDY; DRUG EFFICACY; EVALUATION; FEMALE; LOBAR PNEUMONIA; LOW DRUG DOSE; LUNG ALVEOLUS EPITHELIUM; LUNG PARENCHYMA; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE;

AEROSOLS; ANIMALS; ANTI-BACTERIAL AGENTS; BETA-LACTAMS; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, BACTERIAL; FEMALE; MICE; MICE, INBRED CBA; PENICILLINS; PNEUMONIA, PNEUMOCOCCAL; STREPTOCOCCUS PNEUMONIAE;

EID: 27744455540     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2005.08.022     Document Type: Article

References (29)

1. Centers for Disease Control and Prevention Premature deaths, monthly mortality and monthly physician contacts - United States MMWR Morb Mortal Wkly Rep 46 1997 556 561
2. C. Thornsberry, D.F. Sahm, and L.J. Kelly Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999-2000 Clin Infect Dis 34 Suppl. 1 2002 S4 S16
3. G.V. Doern, K.P. Heilmann, H.K. Huynh, P.R. Rhomberg, S.L. Coffman, and A.B. Brueggemann Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995 Antimicrob Agents Chemother 45 2001 1721 1729
4. J.A. Karlowsky, C. Thornsberry, and I.A. Critchley Susceptibilities to levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis clinical isolates from children: results from 2000-2001 and 2001-2002 TRUST studies in the United States Antimicrob Agents Chemother 47 2003 1790 1797
5. W.A. Craig Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men Clin Infect Dis 26 1998 1 10
6. D. Andes, and W.A. Craig In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations Antimicrob Agents Chemother 42 1998 2375 2379
7. D. Xuan, M. Banevicius, B. Capitano, M.K. Kim, C. Nightingale, and D. Nicolau Pharmacodynamic assessment of ertapenem (MK-0826) against Streptococcus pneumoniae in a murine neutropenic thigh infection model Antimicrob Agents Chemother 46 2002 2990 2995
8. J.D. Knudsen, N. Frimodt-Moller, and F. Espersen Experimental Streptococcus pneumoniae infection in mice for studying correlation of in vitro and in vivo activities of penicillin against pneumococci with various susceptibilities to penicillin Antimicrob Agents Chemother 39 1995 1253 1258
9. E. Azoulay-Dupuis, E. Vallee, B. Veber, J.P. Bedos, J. Bauchet, and J.J. Pocidalo In vivo efficacy of a new fluoroquinolone, sparfloxacin, against penicillin-susceptible and -resistant and multiresistant strains of Streptococcus pneumoniae in a mouse model of pneumonia Antimicrob Agents Chemother 36 1992 2698 2703
10. M.K. Kim, W. Zhou, and P.R. Tessier Bactericidal effect and pharmacodynamics of cethromycin (ABT-773) in a murine pneumococcal pneumonia model Antimicrob Agents Chemother 46 2002 3185 3192
11. P. Moine, E. Vallee, and E. Azoulay-Dupuis In vivo efficacy of a broad-spectrum cephalosporin, ceftriaxone, against penicillin-susceptible and -resistant strains of Streptococcus pneumoniae in a mouse pneumonia model Antimicrob Agents Chemother 38 1994 1953 1958
12. K. Takashima, K. Tateda, and T. Matsumoto Establishment of a model of penicillin-resistant Streptococcus pneumoniae pneumonia in healthy CBA/J mice J Med Microbiol 45 1996 319 322
13. H.L. Hoffman, M.E. Klepser, E.J. Ernst, C.R. Petzold, L.M. Sa'adah, and G.V. Doern Influence of macrolide susceptibility on efficacies of clarithromycin and azithromycin against Streptococcus pneumoniae in a murine lung infection model Antimicrob Agents Chemother 47 2003 739 746
14. Y. Bergeron, N. Ouellet, A.M. Deslauriers, M. Simard, M. Olivier, and M.G. Bergeron Cytokine kinetics and other host factors in response to pneumococcal pulmonary infection in mice Infect Immun 66 1998 912 922
15. F. Dallaire, N. Ouellet, and Y. Bergeron Microbiological and inflammatory factors associated with the development of pneumococcal pneumonia J Infect Dis 184 2001 292 300
16. K. Tateda, K. Takashima, H. Miyazaki, T. Matsumoto, T. Hatori, and K. Yamaguchi Noncompromised penicillin-resistant pneumococcal pneumonia CBA/J mouse model and comparative efficacies of antibiotics in this model Antimicrob Agents Chemother 40 1996 1520 1525
17. J.A. Coil, J.D. Dickerman, and E. Boulton Increased susceptibility of splenectomized mice to infection after exposure to an aerosolized suspension of type III Streptococcus pneumoniae Infect Immun 21 1978 412 416
18. G. Ortiz-Ruiz, J. Caballero-Lopez, I.R. Friedland, G.L. Woods, and A. Carides A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults Clin Infect Dis 34 2002 1076 1083
19. N. Vetter, E. Cambronero-Hernandez, and J. Rohlf A prospective, randomized, double-blind multicenter comparison of parenteral ertapenem and ceftriaxone for the treatment of hospitalized adults with community-acquired pneumonia Clin Ther 24 2002 1770 1785
20. D.M. Musher Streptococcus pneumoniae G.L. Mandell J.E. Bennett R. Dolin Principles and practice of infectious diseases 2000 Churchill Livingstone Philadelphia, PA 2128 2147
21. D.M. Musher, I. Alexandraki, and E.A. Graviss Bacteremic and nonbacteremic pneumococcal pneumonia. A prospective study Medicine (Baltimore) 79 2000 210 221
22. D. Maglio, B. Capitano, M.A. Banevicius, Q. Geng, C.H. Nightingale, and D.P. Nicolau Differential efficacy of clarithromycin in lung versus thigh infection models Chemotherapy 50 2004 63 66
23. D.M. Livermore, A.M. Sefton, and G.M. Scott Properties and potential of ertapenem J Antimicrob Chemother 52 2003 331 344
24. Van Ogtrop ML, Andes D, Craig WA. In vivo antimicrobial activity of MK-0826, a new carbapenem, against various penicillin-resistant pneumococci. In: Program and Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 1998. F-48.
25. C.J. Gill, J.J. Jackson, and L.S. Gerckens In vivo activity and pharmacokinetic evaluation of a novel long-acting carbapenem antibiotic, MK-826 (L-749,345) Antimicrob Agents Chemother 42 1998 1996 2001
26. H.M. Mattoes, M. Banevicius, and D. Li Pharmacodynamic assessment of gatifloxacin against Streptococcus pneumoniae Antimicrob Agents Chemother 45 2001 2092 2097
27. W.A. Craig Post-antibiotic effects in experimental infection models: relationship to in-vitro phenomena and to treatment of infections in man J Antimicrob Chemother 31 Suppl. D 1993 149 158
28. D.E. Briles, M.J. Crain, B.M. Gray, C. Forman, and J. Yother Strong association between capsular type and virulence for mice among human isolates of Streptococcus pneumoniae Infect Immun 60 1992 111 116
29. E. Wang, M. Simard, N. Ouellet, Y. Bergeron, D. Beauchamp, and M.G. Bergeron Pathogenesis of pneumococcal pneumonia in cyclophosphamide-induced leukopenia in mice Infect Immun 70 2002 4226 4238